Treatment-Resistant Depression & Phase Trials

Fifty years ago the U.S. government classified it alongside heroin: no accepted medical use, high potential for abuse, illegal in most of the world. The peer-reviewed data now coming out of Johns Hopkins, Imperial College, and Nature tells a different story, one that has some of the most credentialled neuroscientists alive rethinking how the brain heals. In this episode, Louisa breaks down exactly what psilocybin does to your neurons, why it works where antidepressants stall for decades, and where the research is heading right now. She walks through the default mode network, the self-referential system that turns rigid and hyperactive in depression, and the 2024 Nature study that described psilocybin's effect on it as "massive" disruption. You'll hear how a single dose drove a measurable jump in dendritic spine density within 24 hours, why psilocin binds the TRKB receptor 300 times more strongly than any conventional antidepressant, and how Robin Carhart-Harris's head-to-head trial against escitalopram produced more than double the remission rate. Then she turns to addiction, where psilocybin-assisted therapy reached an 80% smoking abstinence rate at six months in the Johns Hopkins pilot, more than double the best medication available today. She covers the risks the drug-war narrative leaves out, the hard contraindications around psychosis and cardiac history, the April 2026 executive order that accelerated federal review, and why the quality of the subjective experience, measured on the Mystical Experience Questionnaire, may matter to the outcome as much as the molecule itself. You'll also hear about the desynchronization event and what fills the space when the network goes offline, BDNF and how it stacks up against high-intensity exercise, the alcohol and opioid data, HPPD, Australia's 2023 reclassification, Oregon and Colorado's state access frameworks, and why set and setting may be active ingredients in how the treatment works.

Fifty years ago the U.S. government classified it alongside heroin: no accepted medical use, high potential for abuse, illegal in most of the world. The peer-reviewed data now coming out of Johns Hopkins, Imperial College, and Nature tells a different story, one that has some of the most credentialled neuroscientists alive rethinking how the brain heals. In this episode, Louisa breaks down exactly what psilocybin does to your neurons, why it works where antidepressants stall for decades, and where the research is heading right now. She walks through the default mode network, the self-referential system that turns rigid and hyperactive in depression, and the 2024 Nature study that described psilocybin's effect on it as "massive" disruption. You'll hear how a single dose drove a measurable jump in dendritic spine density within 24 hours, why psilocin binds the TRKB receptor 300 times more strongly than any conventional antidepressant, and how Robin Carhart-Harris's head-to-head trial against escitalopram produced more than double the remission rate. Then she turns to addiction, where psilocybin-assisted therapy reached an 80% smoking abstinence rate at six months in the Johns Hopkins pilot, more than double the best medication available today. She covers the risks the drug-war narrative leaves out, the hard contraindications around psychosis and cardiac history, the April 2026 executive order that accelerated federal review, and why the quality of the subjective experience, measured on the Mystical Experience Questionnaire, may matter to the outcome as much as the molecule itself. You'll also hear about the desynchronization event and what fills the space when the network goes offline, BDNF and how it stacks up against high-intensity exercise, the alcohol and opioid data, HPPD, Australia's 2023 reclassification, Oregon and Colorado's state access frameworks, and why set and setting may be active ingredients in how the treatment works. *Reduce your risk of Alzheimer's with my science-backed protocol for women 30+: * https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ *TOPICS DISCUSSED* 00:00 Intro: A Schedule I Drug That's Making Neuroscientists Rethink the Brain 00:39 The Default Mode Network and Your Sense of Self 02:49 How Depression Locks the Brain Into a Rigid Loop 03:23 Where SSRIs Stop Short of the Problem 04:44 The Brain Imaging Data: "Massive" DMN Disruption and Reorganization 06:58 Confirming It in Drug-Naive Brains 08:04 The Rewiring: How Psilocybin Changes Neural Architecture 08:35 Dendritic Spines and Synaptic Density 09:39 How Chronic Stress Shrinks Your Neural Connections 10:16 One Dose, More Connections in 24 Hours (Neuron 2021) 11:02 BDNF, TRKB, and a Signal 300x Stronger Than Antidepressants 13:21 Psilocybin vs the Gold-Standard SSRI 14:37 Double the Remission Rate: The Numbers That Matter 15:53 Side Effects, Durability, and Treatment-Resistant Depression 16:39 The Addiction Breaker: 80% Smoking Abstinence at Six Months 17:36 Alcohol, Opioids, and the Shared Architecture of Addiction 19:10 The Dark Side: Real Risks and Hard Contraindications 22:35 The Policy Earthquake: Executive Orders and FDA Breakthrough Status 24:37 Why It Actually Works: Set, Setting, and the Mystical Experience 26:57 Bringing It All Together _______ *Thank you to our sponsors* Function Health: https://functionhealth.com/LouisaNicola Use code NEURO25 for a $25 credit BASED Bodyworks: https://basedbodyworks.com/ Use code NEURO for 20% off (plus a free toiletry bag with any set) BioOptimizers: https://www.bioptimizers.com/neuro Use code NEURO for 15% off IQBAR: Text NEURO to 64000 for 20% off all IQBAR products plus FREE shipping (Message and data rates may apply)

Learn more about your ad choices. Visit megaphone.fm/adchoices